UCB Reports FINTEPLA Study Showing Sustained LGS Benefits
Atlanta, Georgia, August 5, 2026 UCB has announced the publication of a post hoc analysis in Epilepsia Open demonstrating...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Atlanta, Georgia, August 5, 2026 UCB has announced the publication of a post hoc analysis in Epilepsia Open demonstrating...
Bagsværd, Denmark, August 5, 2026 Novo Nordisk has secured a significant legal victory after the District Court of The...
CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, June 14, 2026 Harbour BioMed has secured a major legal victory in...
Washington, D.C. | January 29, 2026 — The U.S. International Trade Commission (USITC) has formally instituted a Section 337...
